<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114296">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01893567</url>
  </required_header>
  <id_info>
    <org_study_id>GLI.04.SPR.US10243</org_study_id>
    <nct_id>NCT01893567</nct_id>
  </id_info>
  <brief_title>Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%</brief_title>
  <official_title>Subject Reported Target-lesion Numeric Rating Scale Evaluation by Subjects With Plaque Psoriasis Treated With Clobex® (Clobetasol Propionate) Spray 0.05%</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galderma Laboratories, L.P.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galderma Laboratories, L.P.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate the utility of a technological based rating scale
      for assessing improvement in plaque psoriasis with Clobex spray treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Relationship between digital photographs of a target lesion and investigator an subject reported severity scores</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator reported effectiveness scores</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject reported effectiveness scores</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Clobex spray</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobex Spray</intervention_name>
    <arm_group_label>Clobex spray</arm_group_label>
    <other_name>Clobetasol propionate spray</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects 18 years of age or older.

          -  Subjects with a board certified dermatologist clinical diagnosis of active moderate
             to severe psoriasis lesions affecting up to 20% of the body surface area at the
             baseline visit, and in the opinion of the investigator, is otherwise a good candidate
             for treatment with clobetasol propionate 0.05% spray.

          -  Subjects with a target lesion of at least 1 cm x 1 cm

          -  Subjects who agree to be photographed at each visit

        Exclusion Criteria:

          -  Subjects with any condition or presentation that may, in the opinion of the
             investigator, may put the subject at risk, may confound study results, or may
             interfere with participation in the study.

          -  Subjects with any known allergies to any of the ingredients listed on the test
             article label or surgical ink.

          -  Subjects who are pregnant or breast-feeding, or who plan to become pregnant or breast
             feed during the course of the trial.

          -  Subjects that are relatives of the investigator, or are themselves or a relative of
             any study staff or any Galderma employee.

          -  Subjects who have participated in an investigational study within 30 days of
             enrollment; participated in biologic investigational studies within 90 days of
             enrollment, or subjects planning to participate in any other interventional clinical
             research study while enrolled in this trial.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fasahat Hamzavi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamzavi Dermatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hamzavi Dermatology</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 17, 2013</lastchanged_date>
  <firstreceived_date>June 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Erythema Multiforme</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
